Drug Development
Pharmacogenomics of human ABC transporter ABCG2 described
Published in Cancer Weekly, January 24th, 2006
"In the post-genome-sequencing era, emerging genomic technologies are shifting the paradigm for drug discovery and development. Nevertheless, drug discovery and development still remain high-risk and high-stakes ventures with long and costly timelines," scientists writing in the journal Naturwissenschaften reported.
"Indeed, the attrition of drug, candidates in preclinical and development stages is a major problem in drug design. For at least 30% of the candidates, this attrition is due to poor pharmacokinetics and toxicity. Thus, pharmaceutical companies have...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2006-01-24)
More Articles from Cancer Weekly
- Cancer Therapy
Maximum tolerated dose of continuous mitomycin-C infusion determined - Cancer Therapy
Paclitaxel decreased uptake of gemcitabine in human leukemia cells - Drug Development
Organometallic compounds induce cytostatic and cytotoxic effects on cancer cells - Drug Development
PBT-3 caused long-term growth inhibition of K562 solid tumors in vivo - Prostate Cancer
Presence of apoptotic bodies could be used in diagnosis of prostate cancer - Actinic Keratoses
Diclofenac in 2.5% hyaluronan gel is effective for actinic keratoses - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
